| scholarly article | Q13442814 |
| P50 | author | Stéphane Mitrovic | Q64590625 |
| P2093 | author name string | Bruno Fautrel | |
| Eugen Feist | |||
| P2860 | cites work | A proposed classification of the immunological diseases | Q21144701 |
| A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease | Q22251291 | ||
| Still's disease in the adult | Q24514809 | ||
| Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults | Q26852503 | ||
| Adult-onset Still's disease | Q26852631 | ||
| Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease | Q27860821 | ||
| C13orf31 (FAMIN) is a central regulator of immunometabolic function | Q28115290 | ||
| Adult-onset Still's disease with disseminated intravascular coagulation and multiple organ dysfunctions dramatically treated with cyclosporine A | Q28167268 | ||
| Ferritin in autoimmune diseases | Q28237318 | ||
| Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome | Q28239135 | ||
| Primer: inflammasomes and interleukin 1beta in inflammatory disorders | Q28263370 | ||
| Adult-onset Still's disease: Advances in the treatment. | Q30240644 | ||
| Pro-resolving lipid mediators are leads for resolution physiology | Q30829097 | ||
| Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura | Q33343048 | ||
| Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. | Q33359709 | ||
| Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease | Q33371300 | ||
| Thrombotic thrombocytopenic purpura and adult onset Still's disease | Q33383879 | ||
| Thrombotic microangiopathy and purtscher-like retinopathy associated with adult-onset Still's disease: a role for glomerular vascular endothelial growth factor? | Q33386885 | ||
| A case of adult-onset Still's disease complicated by thrombotic thrombocytopenic purpura with retinal microangiopathy and rapidly fatal cerebral edema | Q33401390 | ||
| Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease | Q33408265 | ||
| Life-threatening complications of adult-onset Still's disease | Q33412732 | ||
| Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients | Q33414045 | ||
| An Unusual Case of Adult-Onset Still's Disease with Hemophagocytic Syndrome, Necrotic Leukoencephalopathy and Disseminated Intravascular Coagulation. | Q33414465 | ||
| Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France | Q33578168 | ||
| Soluble CD163. | Q34029313 | ||
| Secondary renal amyloidosis in adult onset Still's disease: case report and review of the literature | Q34036420 | ||
| Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. | Q34042413 | ||
| Association between adult-onset Still's disease and interleukin-18 gene polymorphisms | Q34158398 | ||
| Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions | Q34269827 | ||
| Proinflammatory S100 proteins in arthritis and autoimmune disease | Q34375738 | ||
| Tocilizumab-Induced Acute Liver Injury in Adult Onset Still's Disease | Q34399037 | ||
| Preliminary criteria for classification of adult Still's disease | Q34405573 | ||
| Interleukin 1 inhibition with anakinra in adult-onset Still disease: a meta-analysis of its efficacy and safety | Q34610098 | ||
| Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? | Q34632947 | ||
| The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome | Q34966670 | ||
| ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co | Q34971421 | ||
| Adult-onset Still's disease with disseminated intravascular coagulation and hemophagocytic syndrome: a case report | Q35017649 | ||
| Adult-onset Still's disease. | Q35227924 | ||
| Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still's disease | Q35549311 | ||
| Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis | Q35553556 | ||
| Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases | Q35555229 | ||
| Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences | Q35579173 | ||
| The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still's disease | Q35621852 | ||
| Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still's disease | Q36073815 | ||
| Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review. | Q36195807 | ||
| Pulmonary Arterial Hypertension in Adult-Onset Still's Disease: Rapid Response to Anakinra. | Q36220786 | ||
| Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity | Q36304070 | ||
| HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis | Q36435134 | ||
| Ten years of clinical experience with adult onset Still's disease: is the outcome improving? | Q36645748 | ||
| Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. | Q36855193 | ||
| Pulmonary arterial hypertension in adult onset Still's disease: a case report of a severe complication | Q36886823 | ||
| The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation against self | Q36931672 | ||
| Pulmonary arterial hypertension secondary to adult-onset Still's disease: Response to cyclosporine and sildenafil over 15 years of follow-up | Q37053491 | ||
| S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin | Q37187378 | ||
| TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still's Disease and Their Association with Disease Activity and Clinical Manifestations | Q37210206 | ||
| Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells | Q37240288 | ||
| Adult-onset Still disease | Q37333091 | ||
| Systemic JIA: new developments in the understanding of the pathophysiology and therapy | Q37620829 | ||
| Adult Still's disease: manifestations, disease course, and outcome in 62 patients | Q37670649 | ||
| Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature | Q37829362 | ||
| Pro-resolution immunological networks: binding immunoglobulin protein and other resolution-associated molecular patterns. | Q37970671 | ||
| The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease | Q38003501 | ||
| Ferritin in adult-onset still's disease: just a useful innocent bystander? | Q38005702 | ||
| Inheritance of autoinflammatory diseases: shifting paradigms and nomenclature | Q38093826 | ||
| How should we approach classification of autoinflammatory diseases? | Q38120387 | ||
| A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still's disease: targeting IL-6. | Q38192143 | ||
| Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay | Q38198974 | ||
| Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions | Q38245659 | ||
| Validation of the Fautrel classification criteria for adult-onset Still's disease | Q38651057 | ||
| Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). | Q38652868 | ||
| Coexistence of adult onset Still's disease and polymyositis with rhabdomyolysis successfully treated with methotrexate and corticosteroids | Q38669046 | ||
| Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study | Q38703626 | ||
| An atypical presentation of adult-onset Still's disease complicated by pulmonary hypertension and macrophage activation syndrome treated with immunosuppression: a case-based review of the literature | Q38830731 | ||
| Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1β expression and release | Q38832683 | ||
| The burgeoning field of innate immune-mediated disease and autoinflammation | Q38967233 | ||
| Lessons from characterization and treatment of the autoinflammatory syndromes | Q39025839 | ||
| Successful treatment of refractory adult onset Still's disease with rituximab | Q39095921 | ||
| Calcinosis cutis and intestinal pseudoobstruction in a patient with adult onset Still's disease associated with recurrent relapses of disordered coagulopathy. | Q39513073 | ||
| Adult Still's disease: review of 228 cases from the literature | Q39694157 | ||
| Adult-onset Still's disease; clinical and laboratory features, treatment and progress of 45 cases | Q39782978 | ||
| New Markers for Adult-Onset Still's Disease | Q40056037 | ||
| Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease Successfully Treated with Anakinra. | Q40081000 | ||
| Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. | Q40218234 | ||
| Tocilizumab in adult-onset Still's disease: the Israeli experience | Q40221214 | ||
| Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. | Q40235629 | ||
| Tocilizumab in refractory adult Still's disease | Q40350291 | ||
| Efficacy of abatacept in a refractory case of adult-onset Still's disease. | Q40358353 | ||
| Fatal myocarditis in adult-onset Still disease with diffuse intravascular coagulation. | Q40403433 | ||
| Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France | Q40436579 | ||
| Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. | Q40477212 | ||
| Adult-onset Still disease as the cause of fever of unknown origin | Q40494870 | ||
| Rapid responses to anakinra in patients with refractory adult-onset Still's disease | Q40507008 | ||
| Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations | Q40518156 | ||
| Serum cytokine profiles in patients with adult onset Still's disease | Q40543910 | ||
| Etanercept in the treatment of adult patients with Still's disease | Q40578875 | ||
| Epidemiological study of adult-onset Still's disease using a Japanese administrative database | Q40630580 | ||
| A case of adult onset Still's disease complicated with adult respiratory distress syndrome and disseminated intravascular coagulation | Q40687328 | ||
| Adult Still's disease: a multicenter survey of Japanese patients. | Q40759885 | ||
| A case of adult Still's disease with pulmonary hypertension | Q40765056 | ||
| Adult Still's disease and inflammatory myositis. | Q40810089 | ||
| Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease | Q40819082 | ||
| Adult Still's disease: part I. Manifestations and complications in sixty-five cases in France | Q41163072 | ||
| Adult Still's disease. Part II. Management, outcome, and prognostic factors | Q41163086 | ||
| Severe sore throat as a presenting symptom of adult onset Still's disease: a case series and review of the literature | Q41372194 | ||
| sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia | Q41666895 | ||
| Refractory adult-onset still disease successfully treated with abatacept | Q41931873 | ||
| Interleukin 18: a biomarker for differential diagnosis between adult-onset Still's disease and sepsis | Q42217081 | ||
| Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial | Q42410300 | ||
| On a Form of Chronic Joint Disease in Children | Q42594394 | ||
| A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still's Disease | Q42677427 | ||
| Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration | Q42768414 | ||
| The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study | Q43507241 | ||
| Infliximab in the treatment of adult Still's disease refractory to conventional therapy | Q43640728 | ||
| Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease. | Q43660594 | ||
| Drug-induced hemophagocytosis | Q43996631 | ||
| Two more cases of Still's disease and Kikuchi's | Q44137829 | ||
| Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy | Q44201170 | ||
| Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease | Q44554787 | ||
| Amyloidosis in adult onset Still's disease | Q45055909 | ||
| Markedly increased IL-18 liver expression in adult-onset Still's disease-related hepatitis | Q45128834 | ||
| Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. | Q45242187 | ||
| Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still's disease | Q45334281 | ||
| Pulmonary arterial hypertension and acute respiratory distress syndrome in a patient with adult-onset stills disease | Q47136060 | ||
| Extremely High Serum Ferritin: An Instrumental Marker of Masquerading Adult-Onset Still's Disease with Hemophagocytic Syndrome. | Q47156287 | ||
| Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases | Q47649993 | ||
| Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still's disease: A meta-analysis. | Q49691035 | ||
| Rituximab treatment for pulmonary arterial hypertension in adult-onset Still's disease. | Q51037414 | ||
| Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. | Q51748695 | ||
| Pulmonary arterial hypertension in autoimmune diseases: an analysis of 19 cases from a medical center in northern Taiwan. | Q51811224 | ||
| Lymph node IL-18 expression in adult-onset Still's disease. | Q51824485 | ||
| Complications of adult-onset Still's disease and their management. | Q52586847 | ||
| Autoinflammation. Management of hereditary recurrent fevers--SHARE experience. | Q54252190 | ||
| Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still's disease. | Q54660855 | ||
| Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. | Q54695048 | ||
| Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. | Q54806502 | ||
| Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review. | Q55109011 | ||
| 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension | Q57823897 | ||
| High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation | Q58621869 | ||
| The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients | Q64041811 | ||
| Pulmonary arterial hypertension complicating adult-onset Still's disease | Q64043572 | ||
| Carpal arthritis with ankylosis in late onset still's disease | Q67442609 | ||
| Adult-onset Still's disease | Q67790685 | ||
| Serum ferritin can be useful for diagnosis in adult onset Still's disease | Q69615281 | ||
| Increased serum ferritin levels in adult Still's disease | Q69894994 | ||
| Systemic amyloidosis in a patient with adult onset Still's disease | Q70719873 | ||
| Ferritin levels and response to treatment in patients with Adult Still's disease | Q71608995 | ||
| Serum ferritin and isoferritins are tools for diagnosis of active adult Still's disease | Q72137820 | ||
| Extremely elevated serum ferritin levels in a university hospital: associated diseases and clinical significance | Q72306519 | ||
| Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease | Q73608471 | ||
| Vascular renal AA amyloidosis in adult Still's disease | Q73621810 | ||
| Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease | Q74242469 | ||
| Hyperferritinemia as a marker of Still's disease | Q74314476 | ||
| Proposal for a new set of classification criteria for adult-onset still disease | Q78069999 | ||
| The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis | Q79844555 | ||
| Pulmonary hypertension in a patient with adult-onset Stills disease | Q80001180 | ||
| The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease | Q80665655 | ||
| Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome | Q81158236 | ||
| IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease | Q82669504 | ||
| Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases | Q83192751 | ||
| Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab | Q83274923 | ||
| IL-1 Trap rilonacept in refractory adult onset Still's disease | Q84330833 | ||
| Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis | Q84973391 | ||
| Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis | Q85309904 | ||
| Serum S100A12 may be a useful biomarker of disease activity in adult-onset Still's disease | Q85664363 | ||
| Clinical manifestations of Adult-onset Still's disease presenting with erosive arthritis: Association with low levels of ferritin and Interleukin-18 | Q86525434 | ||
| Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations | Q87162122 | ||
| Successful treatment of refractory adult-onset still disease with canakinumab: a case report | Q87343210 | ||
| Steroid-sparing effects of etanercept in a patient with steroid-dependent adult-onset Still's disease | Q87993394 | ||
| Increased severity and epidermal alterations in persistent versus evanescent skin lesions in adult-onset Still disease | Q88773149 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| adult-onset Still's disease | Q1187697 | ||
| P304 | page(s) | 603-618 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Nature Reviews Rheumatology | Q2107227 |
| P1476 | title | Mechanisms, biomarkers and targets for adult-onset Still's disease | |
| P478 | volume | 14 |
| Q93021023 | Both HLA class I and II regions identified as genome-wide significant susceptibility loci for adult-onset Still's disease in Chinese individuals |
| Q91872188 | Cysteine-Rich Angiogenic Inducer 61 Serves as a Potential Serum Biomarker for the Remission of Adult-Onset Still's Disease |
| Q64093140 | Cytomegalovirus Infection May Trigger Adult-Onset Still's Disease Onset or Relapses |
| Q90152839 | Genetic Association and Expression Correlation between Colony-Stimulating Factor 1 Gene Encoding M-CSF and Adult-Onset Still's Disease |
| Q90394365 | Macrophage activation syndrome in a patient with axial spondyloarthritis on adalimumab |
| Q61449155 | Plasma microRNA Profiles as a Potential Biomarker in Differentiating Adult-Onset Still's Disease From Sepsis |
| Q98467043 | Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still's disease: case report and review of the literature |
| Q90622281 | Tocilizumab-induced anaphylaxis in patients with adult-onset Still's disease and systemic juvenile idiopathic arthritis: a case-based review |
Search more.